City

Cagliari (1)

Fort-de-france (1)

Kinshasa (1)

Nanning (1)

Sarajevo (1)

Overall Status

Completed (2)

Active, not recruiting (1)

Not yet recruiting (1)

Recruiting (1)

Phase

phase 4 (1)

Sponsor

Hui Zhuang (1)

Institute for Public Health of the Federation of Bosnia and Herzegovina (1)

Institute of Tropical Medicine, Belgium (1)

University Hospital Center of Martinique (1)

University of Cagliari (1)

Collaborator

Ecole des Hautes Etudes en Sante Publique (1)

Guangxi Center for Disease Control and Prevention (1)

Institut National de Recherche Biomedicale. Kinshasa, Republique Democratique du Congo (1)

Observatoire Regional de la Sante Provence-Alpes-Cote d'Azur (1)

Sante Publique France Antilles (1)

Unite de Modelisation Marthematique des Maladies Infectieuses UMR 2000, Institut Pasteur (1)

University Hospital Center of Guadeloupe (1)

University of Marseille (UVE UMR IRD_190) (1)

World Health Organization (1)

Intervention

antibodies testing (1)

covid-antibody test (1)

hbv vaccine (engerix-b, recombinant hepatitis b surface antigen, 20µg/ml/vial, glaxosmithkline, belgium) (1)

Study Documents

Intervention Type

diagnostic test (2)

biological (1)

Funder Type

Other (5)

Study Type

Observational (4)

Interventional (1)

seroprevalence

Showing 1 - 5 of 5

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Dengue Vaccine Strategy in Children Aged 9 to 17 Years in French

Recruiting

Dengue
+3 more

Fort-de-france, Martinique

Martinique University Hospital Center

Mar 7, 2022

Population-based Age-stratified Seroepidemiological

Not yet recruiting

Seroprevalence
+2 more

Sarajevo, Bosnia and Herzegovina

Institute for Transfusion Medicine of the Federation of Bosnia a

Nov 16, 2021

COVID-19 Sero-prevalence Health Care Workers Kinshasa

Active, not recruiting

SARS-CoV Infection
Seroprevalence

COVID-antibody test

Kinshasa, Congo, The Democratic Republic of the

Institut Nationale de recherche Biomédicale

Jun 9, 2021

Seroprevalence of SARS-CoV-2 in Unselected Surgical

Completed

SARS-CoV Infection
+2 more

Antibodies testing

Cagliari, Italy

University of Cagliari

Apr 8, 2021

Hepatitis B, Immune Response, Seroprevalence Trial in Nanning (HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen,

Completed

Hepatitis B
+2 more

HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)

Nanning, Guangxi, China

Guangxi Centers for Disease Control and Prevention

May 23, 2013